
CIDP
Chronic Inflamatory Demyelinating PolyneuropathyDe Daniel SchwartzDuração2h 47m
Sobre este audiolivro
CIDP: Chronic Inflammatory Demyelinating Polyneuropathy — A Complete Guide by Daniel Schwartz is a comprehensive, accessible 2026 guide to one of the most underdiagnosed autoimmune nerve diseases. CIDP occurs when the immune system mistakenly attacks the myelin sheath surrounding peripheral nerves, causing progressive weakness, numbness, pain, and loss of balance that unfolds over months to years — distinguishing it from the acute, self-limited Guillain-Barré Syndrome it closely resembles. Schwartz walks readers through the full arc of the disease. Written for patients, families, nursing and medical students, and curious non-specialists alike, the book pairs clear plain-language explanations with comparison tables, a full glossary, and practical appendices — symptom diaries, medication logs, and a guide to reading nerve conduction reports — empowering readers to understand their diagnosis and participate meaningfully in their own care.
Detalhes do audiolivro
GêneroHealth and Wellness
Duração2 h 47 min
Narrado porOuça com mais de 1.000 vozes
FormatoeBook com áudio
Data de publicação13 de abr. de 2026
IdiomaInglês
Sumário
1Introduction
2Foreword: A Note to Readers
3Chapter 1: What Is CIDP?
41.1 The Big Picture
51.2 Peripheral Nerves: What Are They?
Mostrar todos os capítulosVer menos
61.3 The Word "Demyelinating" — What It Means
71.4 Chronic vs. Acute: How CIDP Differs from GBS
81.5 Why CIDP Is Often Underdiagnosed
9Chapter 2: A History of CIDP
102.1 Early Observations of Peripheral Nerve Disease
112.2 Guillain, Barré, and Strohl (1916)
122.3 The 1950s and 1960s: A Chronic Form Emerges
132.4 Peter Dyck and the Formal Definition (1975)
142.5 The 1980s–1990s: New Treatments and Confirmation
152.6 The 2000s–2010s: Subtypes and Biological Targets
162.7 The 2020s: Targeted Therapies and Personalized Medicine
17Chapter 3: Epidemiology — Who Gets CIDP?
183.1 How Common Is CIDP?
193.2 Age and Sex Distribution
203.3 Geographic and Ethnic Distribution
213.4 Risk Factors and Associated Conditions
223.5 Economic and Social Burden
23Chapter 4: Pathology — What Happens Inside the Nerve?
244.1 The Immune Attack: An Overview
254.2 The Blood-Nerve Barrier
264.3 The Node of Ranvier: Architecture and Vulnerability
274.4 Demyelination, Remyelination, and Onion Bulbs
284.5 What the Nerve Biopsy Shows
294.6 Key Antibody Targets: A New Era of Understanding
304.7 Recognized Clinical Subtypes of CIDP
31Chapter 5: Symptoms — What Does CIDP Feel Like?
325.1 The Typical Presentation
335.2 Motor Symptoms — Weakness and Movement Problems
345.3 Sensory Symptoms — Abnormal Feelings
355.4 Balance and Gait Problems
365.5 Less Common Symptoms
375.6 Clinical Courses Over Time
385.7 Impact on Daily Life and Quality of Life
39Chapter 6: Diagnosis — How Is CIDP Identified?
406.1 Why Diagnosis Is Challenging
416.2 Clinical History and Neurological Examination
426.3 Nerve Conduction Studies (NCS) and Electromyography (EMG)
436.4 Cerebrospinal Fluid (CSF) Analysis
446.5 MRI of the Spine and Peripheral Nerves
456.6 Blood Tests
466.7 Nerve Biopsy
476.8 Diagnostic Certainty Levels and the Treatment Trial: 6.8.1 How Many Nerves Must Be Abnormal? The 2021 NCS Demyelination Criteria
48Chapter 7: Treatment — Managing and Treating CIDP
497.1 The Goals and Philosophy of CIDP Treatment
507.2 First-Line Treatments